|
Report Date : |
11.01.2013 |
IDENTIFICATION DETAILS
|
Name : |
HAMARI CHEMICALSLTD |
|
|
|
|
Registered Office : |
1-4-29 Kunijima Higashi-Yodogawaku Osaka 533-0024 |
|
|
|
|
Country : |
Japan |
|
|
|
|
Financials (as on) : |
30.09.2011 |
|
|
|
|
Date of Incorporation : |
December 1948 |
|
|
|
|
Com. Reg. No.: |
1200-01-052678 (Osaka-Higashi-Yodogawaku) |
|
|
|
|
Legal Form : |
Limited Company |
|
|
|
|
Line of Business : |
Manufacturer of API & pharmaceutical ingredients |
|
|
|
|
No. of Employees : |
81 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – June 30th, 2012
|
Country Name |
Previous Rating (31.03.2011) |
Current Rating (30.06.2012) |
|
Japan |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
JAPAN - ECONOMIC OVERVIEW
In the years following World War II, government-industry cooperation, a strong work ethic, mastery of high technology, and a comparatively small defense allocation (1% of GDP) helped Japan develop a technologically advanced economy. Two notable characteristics of the post-war economy were the close interlocking structures of manufacturers, suppliers, and distributors, known as keiretsu, and the guarantee of lifetime employment for a substantial portion of the urban labor force. Both features are now eroding under the dual pressures of global competition and domestic demographic change. Japan's industrial sector is heavily dependent on imported raw materials and fuels. A tiny agricultural sector is highly subsidized and protected, with crop yields among the highest in the world. Usually self-sufficient in rice, Japan imports about 60% of its food on a caloric basis. Japan maintains one of the world's largest fishing fleets and accounts for nearly 15% of the global catch. For three decades, overall real economic growth had been spectacular - a 10% average in the 1960s, a 5% average in the 1970s, and a 4% average in the 1980s. Growth slowed markedly in the 1990s, averaging just 1.7%, largely because of the after effects of inefficient investment and an asset price bubble in the late 1980s that required a protracted period of time for firms to reduce excess debt, capital, and labor. Measured on a purchasing power parity (PPP) basis that adjusts for price differences, Japan in 2011 stood as the fourth-largest economy in the world after second-place China, which surpassed Japan in 2001, and third-place India, which edged out Japan in 2011. A sharp downturn in business investment and global demand for Japan's exports in late 2008 pushed Japan further into recession. Government stimulus spending helped the economy recover in late 2009 and 2010, but the economy contracted again in 2011 as the massive 9.0 magnitude earthquake in March disrupted manufacturing. Electricity supplies remain tight because Japan has temporarily shut down almost all of its nuclear power plants after the Fukushima Daiichi nuclear reactors were crippled by the earthquake and resulting tsunami. Estimates of the direct costs of the damage - rebuilding homes, factories, and infrastructure - range from $235 billion to $310 billion, and GDP declined almost 0.5% in 2011. Prime Minister Yoshihiko NODA has proposed opening the agricultural and services sectors to greater foreign competition and boosting exports through membership in the US-led Trans-Pacific Partnership trade talks and by pursuing free-trade agreements with the EU and others, but debate continues on restructuring the economy and reining in Japan's huge government debt, which exceeds 200% of GDP. Persistent deflation, reliance on exports to drive growth, and an aging and shrinking population are other major long-term challenges for the economy.
Source
: CIA
HAMARI CHEMICALSLTD
REGD NAME: Hamari
Yakuhin Kogyo KK
MAIN OFFICE: 1-4-29
Kunijima Higashi-Yodogawaku Osaka 533-0024 JAPAN
Tel:
06-6322-0191 Fax: 06-6323-2115
URL: http://www.hamarichemicals.com
E-Mail address: (thru the URL)
Mfg of API &
pharmaceutical ingredients
Tokyo, Kobe
USA (2), Germany,
China
At the caption
address
TOKIO TAKAMI, PRES Shigeo Takami, ch
Kokichi Yoshida,
dir Chiharu Mori, dir
Yen Amount: In million Yen, unless otherwise stated
FINANCES FAIR A/SALES Yen 6,385 M
PAYMENTS NO
COMPLAINTS CAPITAL Yen 120 M
TREND UP WORTH Yen 1,329 M
STARTED 1948 EMPLOYES 81
MFR OF API & PHARMACEUTICAL INGREDIENTS.
FINANCIAL SITUATION CONSIDERED FAIR AND GOOD
FOR ORDINARY BUSINESS ENGAGEMENTS.
The subject company was
established by Shigeo Takami in order to make most of his experience in the
subject line of business. This is a
specialized mfr of API and pharmaceutical ingredients (See OPERATION). Operates 4 overseas
branches: USA (2), Germany and China.
Goods are both imported and exported.
The sales volume for
Sept/2011 fiscal term amounted to Yen 6,385 million, a 14% up from Yen 5,601
million in the previous term. The
recurring profit was posted at Yen 158 million and the net profit at Yen 35
million, respectively, compared with Yen 136 million recurring profit and yen
73 million net profit, respectively, a year ago.
For the term that ended
Sept 2012 the recurring profit was projected at Yen 160 million and the net
profit at Yen 40 million, respectively, on a 3% rise in turnover, to Yen 6,600
million. Final results are yet to be released.
The financial
situation is considered FAIR and good for ORDINARY business engagements.
Date Registered: Dec
1948
Regd No.:
1200-01-052678 (Osaka-Higashi-Yodogawaku)
Legal Status: Limited Company (Kabushiki Kaisha)
Authorized: 9.6 million shares
Issued: 2.4 million shares
Sum: Yen 120 million
Major
shareholders (%): Hamari Sangyo KK (34), Takeda Pharmaceutical Co (20), Shigeo Takami
(16), Tokio Takami (7), Kazuko Takami (2)
No. of shareholders: 61
Nothing
detrimental is known as to the commercial morality of executives.
Activities: Manufactures API
and pharmaceutical ingredients: amino acid derivatives, peptides, intermediates
for API, vitamin & dietary supplements, glycosides, API, other (--100%).
Clients: [Mfrs, wholesalers]
Hamari Sangyo KK, Daiichi Sankyo Propharma, Zeria Pharmaceutical, Takeda
Pharmaceutical Co, other
No. of accounts:
300
Domestic areas of
activities: Nationwide
Suppliers: [Mfrs,
wholesalers] Yonezawa Hamari Chemicals, Hamari Sangyo Co, Aliment Ind, Shanghai
Chem Partner, other
Payment record: No Complaints
Location: Business area in
Osaka. Office premises at the caption
address are owned and maintained satisfactorily.
Bank References:
SMBC (Osaka-Chuo)
MUFG (Tenma)
Relations:
Satisfactory
(In Million
Yen)
|
Terms Ending: |
30/09/2012 |
30/09/2011 |
30/09/2010 |
30/09/2009 |
|
|
Annual
Sales |
|
6,600 |
6,385 |
5,601 |
5,842 |
|
Recur.
Profit |
|
160 |
158 |
136 |
|
|
Net
Profit |
|
40 |
35 |
73 |
56 |
|
Total
Assets |
|
|
6,383 |
6,741 |
6,625 |
|
Current
Assets |
|
|
4,146 |
4,493 |
|
|
Current
Liabs |
|
|
3,050 |
3,427 |
|
|
Net
Worth |
|
|
1,329 |
1,305 |
1,241 |
|
Capital,
Paid-Up |
|
|
120 |
120 |
120 |
|
Div.P.Share(¥) |
|
|
2.00 |
2.00 |
2.00 |
|
<Analytical Data> |
(%) |
(%) |
(%) |
(%) |
|
|
S.Growth Rate |
3.37 |
14.00 |
-4.13 |
-6.17 |
|
|
Current Ratio |
|
.. |
135.93 |
131.11 |
.. |
|
N.Worth Ratio |
.. |
20.82 |
19.36 |
18.73 |
|
|
R.Profit/Sales |
|
2.42 |
2.47 |
2.43 |
.. |
|
N.Profit/Sales |
0.61 |
0.55 |
1.30 |
0.96 |
|
|
Return On Equity |
.. |
2.63 |
5.59 |
4.51 |
|
Notes: Forecast
(or estimated) figures for the 30/09/2012 fiscal term.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.54.63 |
|
|
1 |
Rs.87.50 |
|
Euro |
1 |
Rs.71.32 |
INFORMATION DETAILS
|
Report
Prepared by : |
PRL |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.